

# Assessing Impairment of Executive Function and Psychomotor Speed in Premanifest and Manifest Huntington's Disease Gene-expansion Carriers

Ida Unmack Larsen,<sup>1,2</sup> Tua Vinther-Jensen,<sup>1,3</sup> Anders Gade,<sup>2</sup> Jørgen Erik Nielsen,<sup>1,3</sup> AND Asmus Vogel<sup>1</sup>

<sup>1</sup>Neurogenetics Clinic, Danish Dementia Research Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

<sup>2</sup>Department of Psychology, University of Copenhagen, Copenhagen, Denmark

<sup>3</sup>Department of Cellular and Molecular Medicine, Section of Neurogenetics, University of Copenhagen, Copenhagen, Denmark

(RECEIVED August 6, 2014; FINAL REVISION January 16, 2015; ACCEPTED January 19, 2015)

## Abstract

Executive functions (EF) and psychomotor speed (PMS) has been widely studied in Huntington's disease (HD). Most studies have focused on finding markers of disease progression by comparing group means at different disease stages. Our aim was to investigate performances on nine measures of EF and PMS in a group of premanifest and manifest HD-gene expansion carriers and to investigate which measures were most sensitive for assessment of individual patients by analyzing frequencies of *impaired* performances relative to healthy controls. We recruited HD gene-expansion carriers, 48 manifest and 50 premanifest and as controls 39 healthy gene-expansion negative individuals. All participants underwent neurological examination and neuropsychological testing with nine cognitive measures. The frequency of impairment was investigated using cutoff scores. In group comparisons the manifest HD gene-expansion carriers scored significantly worse than controls on all tests and in classification of individual scores the majority of scores were classified as *probably impaired* (10<sup>th</sup> percentile) or *impaired* (5<sup>th</sup> percentile) with Symbol Digit Modalities Test (SDMT) being the most frequently impaired. Group comparisons of premanifest HD gene-expansion carriers and healthy controls showed significant differences on SDMT and Alternating fluency tests. Nevertheless the frequencies of *probably impaired* and *impaired* scores on individual tests were markedly higher for Alternating and Lexical fluency tests than for SDMT. We found distinct group differences in frequency of impairment on measures of EF and PMS in manifest and premanifest HD gene-expansion carriers. Our results indicate to what degree these measures can be expected to be clinically impaired. (*JINS*, 2015, 21, 193–202)

**Keywords:** Neuropsychology, Assessment, Cognition, Executive tests, Neurodegenerative disease, Verbal fluency

## INTRODUCTION

Huntington's disease (HD) is an autosomal dominantly inherited neurodegenerative disorder presenting with progressive motor, neuropsychiatric, and cognitive symptoms. The disease is caused by an expanded CAG repeat in the huntingtin gene (The Huntington's Disease Collaborative Research Group, 1993). The cognitive deterioration in HD is commonly observed before the onset of motor symptoms and is thought to be caused by dysfunction of the frontostriatal circuits due to gradual degeneration of the caudate nucleus (Alexander, DeLong, & Strick, 1986; Royall et al., 2002; Tabrizi et al., 2011). Due to the dysfunction in frontostriatal circuits the first

signs of cognitive impairment are expected to be in cognitive functions associated with the prefrontal cortex (Montoya, Price, Mear, & Lepage, 2006; Royall et al., 2002). Studies on cognition in HD have consistently shown that the earliest signs of cognitive impairments are found in psychomotor speed, emotion recognition, and executive functions (Dumas, van den Bogaard, Middelkoop, & Roos, 2013; Paulsen, 2011; Stout et al., 2011). Cognitive impairment has significant impact on patients' ability to maintain everyday functioning and on the quality of life of both patients and caregivers (Paulsen, 2011; Ready, Mathews, Leserman, & Paulsen, 2008). Thus clinical assessment of cognitive impairment in HD gene-expansion carriers is essential.

Executive functions is a generic term for cognitive functions thought to be mediated by the prefrontal cortex such as planning, decision making, monitoring, control of action, cognitive flexibility and set-shifting (Lezak, 2004). Impairment of executive functions can be debilitating and

Correspondence and reprint requests to: Ida Unmack Larsen, Danish Dementia Research Centre, dep. 6991, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Ø. E-mail: Ida.unmack.larsen.01@regionh.dk

interferes with the ability to maintain everyday functioning (Burgess et al., 2006; Jurado & Rosselli, 2007). Deficits in executive functions can also interfere with other cognitive functions such as memory retrieval and prospective memory (Nicoll et al., 2014). Executive functions have been studied intensively in HD (Dumas et al., 2013; Paulsen, 2011). Some studies used measures that have been adapted from experimental psychology and are not included in a typical neuropsychological assessment (Stout et al., 2011). Other studies have demonstrated that patients with HD are impaired on neuropsychological tests tapping executive functions such as the Stroop test, Verbal fluency, Wisconsin Card Sorting Test, Tower of London, Symbol Digit Modalities Test, and Trail Making Test B (Brandt et al., 2008; Paulsen, 2011; Peinemann et al., 2005; Snowden, Craufurd, Griffiths, Thompson, & Neary, 2001; Unschuld et al., 2013). For this study, we used measures of executive function and psychomotor speed that have proven sensitive to HD in previous studies (e.g., SDMT, Stroop test, lexical fluency, TMT B) (Larsson, Almkvist, Luszcz, & Wahlin, 2008; Stout et al., 2011, 2014; Tabrizi et al., 2012) and new measures that have not been used to study HD before to our knowledge (e.g., Hayling and Brixton test, Alternating fluency, Zoo map test).

Most studies on cognition in HD aim to find sensitive cognitive measures that can serve as markers of disease progression by comparing group means at different disease stages. A statistically significant difference in mean score does not indicate the frequency of performances that can be classified as *cognitively impaired*. On neuropsychological tests the variation of scores is often large and increases with disease progression. So when choosing tests for clinical neuropsychological assessment, group differences in mean scores may be misleading. To our knowledge only two studies have investigated the frequency of cognitive impairment in HD gene-expansion carriers (Duff et al., 2010; Vinther-Jensen et al., 2014). These studies have investigated the frequency of a more global cognitive impairment. This study is the first to investigate specifically the frequency of *impaired* performances on a wide range of individual neuropsychological tests of executive functions and psychomotor speed.

The overall aim of this study was to get a better understanding of which of the measures of executive function and psychomotor speed used here were most sensitive for clinical assessment of individual patients. This was done by (1) Investigating cognitive performances on nine measures of psychomotor speed and executive functions in a consecutive group of premanifest and manifest HD-gene expansion carriers and (2) analyzing the frequencies of *impaired* performances relative to healthy controls on these neuropsychological tests in premanifest and manifest HD gene-expansion carriers.

## METHODS

### Participants

Participants were recruited from January 2012 to March 2013 from the Neurogenetics Clinic, Danish Dementia Research

Centre, Rigshospitalet. Ninety-eight HD gene-expansion carriers with a CAG repeat  $\geq 39$ , a Unified Huntington's Disease Rating Scale-99 total motor score  $\leq 35$  (UHDRS-TMS) (Huntington Study Group, 1996), a Mini Mental State Examination (MMSE) score  $\geq 24$ , and a Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) score  $\geq 19$  were included in the study. HD gene-expansion carriers with a UHDRS-TMS score of  $>5$  were classified as *manifest HD gene-expansion carriers* ( $N = 48$ ). If the score was  $\leq 5$ , indicating no substantial motor signs, a classification of *premanifest HD gene-expansion carrier* ( $N = 50$ ) was used. The UHDRS-TMS is a scale developed to standardize motor rating. Motor signs are evaluated on 31 items each rated (0–4) from normal to severe impairment (Huntington Study Group, 1996). Exclusion criteria were other neurological illness, ongoing alcohol or drug abuse, and having a native language other than Danish. Thirty-nine healthy HD gene-expansion negative individuals (who were offspring of a HD gene-expansion carrier and had been genetically tested with a CAG repeat length of less than 30) were included as controls. All individuals had gone through genetic counseling and were informed of their genetic status before (and independent from) study enrollment.

### Procedure

The study was approved by the Ethics Committee of the Capital Region of Denmark (H2-2011-085), and written informed consent was obtained from each participant before enrolment. All participants had a minimum of two planned visits. At one visit psychiatric screening, Hamilton Depression Rating Scale (HAM-D), physical and neurological examinations were performed. At another visit neuropsychological testing was performed. The two visits were preplanned and performed in random order, 83.2% of the evaluations were performed within 14 days of each other and only 3 (2.1%) of the evaluations were performed more than 3 months apart. All evaluations were performed blinded to one another. The same physician and the same neuropsychologist performed all examinations.

### Neuropsychological Testing

All participants were tested with an extensive 3-hr battery of neuropsychological tests, including tests of attention, memory and visuospatial functions. The results from these tests have been published elsewhere (Vinther-Jensen et al., 2014). The battery also included tests of social cognition (which will be published elsewhere).

The tests were administered in a fixed order. General IQ levels were estimated using an education index score and DART (Danish Adult Reading Test), an equivalent of the NART (Nelson & O'Connell, 1978). DART was used because measures of pronunciation of irregular words are highly correlated with general measures of intelligence and have been shown to be relatively unaffected by dementia

processes in other neurodegenerative diseases in the early stages of disease (O'Carroll, 2014). Crawford, Parker, and Besson (1988) found that NART score was relatively more resistant to cognitive decline than WAIS vocabulary score in HD. Also general intelligence or crystallized intelligence has been shown to be less sensitive to frontal lobe damage than fluid intelligence (Duncan, Burgess, & Emslie, 1995; Royall et al., 2002) and thus was expected to be less affected by executive deficits. The education index score (range, 8–17) was calculated as the sum of years of schooling (range, 7–12) and the level of post-secondary education stratified into groups (range, 1–5) based on the method previously used by Mortensen and Gade (1993). Motor speed was evaluated using the Trail Making Test 0 (TMT 0), which is an equivalent to the Trail Making Test for motor speed from the D-KEFS battery, but adapted in size to be the same as the TMT B used in our study. TMT 0 was used as a covariate to control for the effect of motor speed on performance.

The test battery consisted of one test of psychomotor speed and eight different tests of executive functions. We based our choice of executive function tests on the Factor Analysis made by Testa, Bennett, and Ponsford (2012): Stroop interference test and Trail Making Test B were thought to measure set-shifting and interference management, Zoo map test and Brixton test was thought to measure task analysis, The Hayling test was thought to reflect response inhibition and the lexical fluency test was thought to measure strategy generation and regulation. Alternating fluency was not part of the factor analysis by Testa et al. (2012), but have been associated with internal attentional control and set-shifting difficulties in Parkinson's disease (Zec et al., 1999), thus we chose to make an additional label called internal attentional control.

### *Psychomotor speed*

*Symbol Digit Modalities Test (SDMT) (Smith, 1982).* The SDMT involves a simple substitution task using a reference key with nine different digit–symbol pairs. Each participant was given 90 s to pair specific numbers with given abstract symbols. Number of correct responses was used for analysis.

### *Set-shifting and interference management*

*Trail Making Test B (TMT B) (Reitan, 1955).* The participants were asked to connect circles alternating between numbers in numeric order and letters in alphabetical order. The time to completion was recorded.

*Stroop Interference Test (Stroop, 1935).* This 100-word version of the Stroop task consisted of a simple reading task and an interference test. In the interference test the name of the color and the color of the ink did not correspond, for example the word blue could be written in green ink, and the participants were asked to name the colors instead of reading the words. Participants were instructed to complete as fast as

possible and to correct their mistakes. Only the time to completion for the interference test was used for analysis.

### *Internal attentional control*

*Lexical alternating fluency.* This fluency test was developed by the researchers based on the most common first-letters in the Danish language besides S and F. The participants were asked to produce as many different words as possible in one minute, alternating between words beginning with the letter K and words beginning with the letter B. It was emphasized that it could be all types of words except for proper nouns. The number of correct responses was recorded, and improper alternations were counted as incorrect.

*Semantic/lexical alternating fluency.* This fluency test was developed by the researchers based on a category that was thought to be very broad and one of the most common first-letters in the Danish language besides S, F, K, and B. The participants were asked to produce as many different words as possible in one minute alternating between types of food and words beginning with the letter D. They were told it could be anything you can eat, and all words beginning with the letter D except for proper nouns. The number of correct responses was recorded; improper alternations were counted as incorrect.

### *Task analysis*

*The Brixton test (Burgess & Shallice, 1997)* is a rule attainment task. The test consists of a stimulus book with each page showing the same basic array of ten circles set in two rows of five with each circle numbered from one to ten. On each page, one circle is blue. The position of the blue circles differs from page to page, and the participants were asked to guess where the blue circle would be on the next page, by trying to see a pattern based on previous pages. No feedback was given. The number of errors (range, 0–54) was recorded.

*Zoo map test* from the Behavioral Assessment of the Dysexecutive Syndrome battery (Wilson, Alderman, Burgess, Emslie, & Evans, 1996) is a test of the ability to formulate and implement a plan (part one) and to follow a predefined plan (part two). The participant was asked to plot or follow a route through a map without breaking certain rules. The test was scored based on successful implementation of the plan, and penalties were given for rule breaks. The time spent on part one and total score (correct order of places visited minus penalties; maximum score for part one plus two was 16) were used for analysis.

### *Strategy generation and regulation*

*Lexical fluency (Lezak, 2004).* The participants were asked to produce as many words as possible within one minute beginning with each of the letters F, A, and S. It was emphasized that it could be all words in Danish except proper

nouns. The number of different words produced with both F, A, and S were recorded and added together for total score.

### Response inhibition

*The Hayling test\** (Burgess & Shallice, 1997) is a test of response initiation and response inhibition. It consists of two sections (part one and two) of 15 sentences each where the last word is missing. The participant was asked to give a verbal response and complete the sentence as quickly as possible. In part one the participant was asked to complete the sentence sensibly, in part two (*Hayling interference test*) the participant was asked to give a word that was unconnected to the sentence in every way. The test manual guidelines were used to clarify whether the response was completely unconnected to the sentence (0), somewhat connected to the sentence (category B error) or a completely plausible completion of the sentence (category A error). Only the response time for the Hayling interference test was used in this study.

### Data Analyses

Group comparisons were performed using one-way analysis of variance (ANOVA). To control for multiplicity an alpha level of .05 and Dunnett *t* test (2-sided) adjustment was applied for post hoc comparisons (Dunnett *t* tests treat one group as a control, and compare all other groups against it). Between group differences were evaluated using analyses of covariance (backward stepwise elimination) controlling for education, age, trail 0-score, and DART-score, and also correlation of test performances and scores on HAM-D was performed.

Effect sizes (Cohen's *d*) were calculated by the following formula (Field, 2013):

$$\text{Effect size} = \frac{\text{Mean HD group} - \text{Mean Control group}}{\text{Pooled SD}}$$

Effect of disease burden for premanifest HD gene-expansion carriers was analyzed by calculating the CAG-Age Product Scaled (CAPs) formulated by the PREDICT-HD study (Zhang et al., 2011) by the following equations:

$$\text{CAP} = \text{age}_0 \times (\text{cag} - 33.6600) \text{ and } \text{CAPs} = \frac{\text{CAP}}{432.3326}$$

The premanifest HD gene-expansion carriers were divided into *low-CAPs* with a CAPs score of  $\leq 0.67$  and *medium/high-CAPs* with a CAPs score of  $> 0.67$ . A *low-CAPs* score indicates that a person is far from predicted motor onset and a medium/high-CAPs score indicates that a person is closer to predicted motor onset. Group differences were investigated between the *low-* and *medium/high-* CAPs and healthy controls using ANOVA with an alpha level of .05. Dunnett (2 sided) adjustment was applied for *post hoc* comparisons.

\* The Hayling Test. Copyright © (1997) by Pearson Assessment (Tom Shallice). Copyright © (2011) by Pearson Assessment, Reproduced with permission. All rights reserved.

To investigate the number of HD gene-expansion carriers that could be classified as *probably impaired/impaired* on the neuropsychological tests the healthy control group was used as reference. Scores below the 10<sup>th</sup> percentile were classified as *probably impaired*, and scores below the 5<sup>th</sup> percentile were classified as *impaired*. Odds ratios were calculated for the frequencies of scores below the 10<sup>th</sup> percentile in the premanifest and the manifest HD-gene expansion carriers relative to healthy controls.

## RESULTS

Table 1 shows the background information for HD gene-expansion carriers and healthy controls. The manifest HD gene-expansion carriers were significantly older and significantly less educated and, furthermore, had significantly lower scores on DART, TMT 0, MoCA and MMSE relative to the premanifest HD gene-expansion carriers and healthy controls.

Table 2 shows the results from the neuropsychological tests and significance levels from the group comparisons before covariance analysis. The manifest HD gene-expansion carriers scored significantly lower on all neuropsychological tests as compared to healthy controls ( $p < .0001$ ). After controlling for education, age, TMT 0-score and DART-score by analyses of covariance (taking multiplicity into account) the group comparisons between healthy controls and the manifest HD-gene expansion carriers remained significant on all neuropsychological tests except for the Brixton test, Zoo map test part 1 and Zoo map total. The premanifest HD gene-expansion carriers scored significantly lower than controls on SDMT, Semantic/lexical alternating fluency and Lexical alternating fluency. After controlling for education, age, TMT 0-score, and DART-score by analyses of covariance (taking multiplicity into account) the group comparisons between healthy controls and the premanifest HD-gene expansion carriers remained significant for SDMT and

**Table 1.** Background information for HD gene-expansion carriers and healthy controls

	Healthy controls <i>N</i> = 39	Premanifest HD gene-expansion carriers <i>N</i> = 50	Manifest HD gene-expansion carriers <i>N</i> = 48
Sex (m/f)	17/22	29/21	29/19
Age (years)	40 (20–68)	36 (20–54)†	51 (24–75)*
Education index	14 (10–17)	14 (11–17)†	13 (8–17)*
DART	28 (13–44)	24 (7–38)	23 (1–41)*
Trail Making 0	9 (5–20)	11 (5–21)	18 (6–38)
MMSE	30 (27–30)	29 (26–30)	28 (24–30)*
MoCA	28 (25–30)	28 (25–30)†	26 (21–30)*
CAG-repeat length	18 (17–26)	42 (39–48)*†	43 (40–53)*
UHDRS total motor score	0 (0–4)	2 (0–5)	19 (7–35)*

Note: Results shown as median (range).

\*Significant difference from healthy controls,  $p < 0.05$ .

†Significant difference from manifest HD gene-expansion carriers,  $p < 0.01$ .

**Table 2.** Test performances for HD gene-expansion carriers and healthy controls

	Healthy controls N = 39	Premanifest HD gene-expansion carriers N = 50	Manifest HD gene- expansion carriers N = 48	Effect size (Cohen's d) Premanifest relative to controls†	Effect size (Cohen's d) Manifest relative to controls†
<b>Psychomotor speed</b>					
SDMT (number correct)	55.2 (10.1)	49.7 (8.2)*	29.9 (8.5)*	-0.6	-2.7
<b>Set-shifting, interference management, and internal attentional control</b>					
Semantic/lexical alternating fluency (number correct)	13.5 (3.7)	11.5 (3.3)*	7.9 (2.8)*	-0.6	-1.7
Lexical alternating fluency (number correct)	16.5 (3.2)	14.8 (3.2)*	10.1 (3.9)*	-0.5	-1.8
Stroop interference test (seconds)	109.5 (21.7)	119.0 (21.2)	174.5 (64.5)*	-0.4	-1.3
TMT B (seconds)	58.0 (19.8)	62.0 (16.8)	124.0 (53.2)*	-0.2	-1.6
<b>Strategy generation and regulation</b>					
Lexical fluency (number correct)	41.2 (11.5)	37.2 (10.2)	27.3 (10.6)*	-0.4	-1.3
<b>Task analysis</b>					
Brixton test (errors)	11.6 (5.2)	10.8 (4.1)	15.1 (6.9)*	-0.2	-0.6
Zoo map total (number correct)	14.5 (2.4)	14.7 (2.4)	11.4 (5.1)*	-0.1	-0.8
Zoo map test part 1 (seconds)	208.2 (140.6)	200.3 (136.1)	346.0 (189.3)*	-0.1	-0.8
<b>Response inhibition</b>					
Hayling interference test (seconds)	37.0 (29.4)	47.6 (27.9)	86.7 (60.1)*	-0.4	-1.0

Note. Results shown as mean (SD).

\*Significant difference from healthy controls,  $p < 0.05$ .

†Negative numbers indicates worse performance relative to controls.


Semantic/lexical alternating fluency. There was a significant positive effect of HAM-D score on Hayling interference test in the premanifest group; otherwise HAM-D score was not significantly associated with neuropsychological test performances in either manifest or premanifest HD gene-expansion carriers.

Premanifest HD gene-expansion carriers were divided into a *low-CAPs* group ( $N = 23$ ) and a *medium/high-CAPs* group ( $N = 27$ ). Compared to healthy controls the *medium/high-CAPs* group scored significantly lower on SDMT ( $p = .0001$ ), Semantic/lexical alternating fluency ( $p = .004$ ), Stroop interference test ( $p = .009$ ), and Lexical alternating fluency ( $p = .040$ ).


Figure 1 shows the percentage of premanifest HD gene-expansion carriers classified as *probably impaired/impaired* on the neuropsychological tests. Alternating fluency tests and Lexical fluency were the tests with the highest frequency of impairment among the premanifest HD gene-expansion carriers. Lexical alternating fluency was the most frequently impaired test with 34% of scores below the 10<sup>th</sup> percentile and 16% of scores below the 5<sup>th</sup> percentile.

Figure 2 shows the percentage of manifest HD gene-expansion carriers classified as *probably impaired/impaired* on the neuropsychological tests. The large majority of the manifest HD-gene expansion carriers were *probably impaired* or *impaired* on all tests (except for the Brixton test). As compared to the results from the premanifest HD gene-expansion carriers there was smaller difference between the number of participants that were classified as *probably impaired* and *impaired*. The most frequently impaired test in manifest HD gene-expansion carriers was SDMT (89.6% of scores falling below the 10<sup>th</sup> percentile and 87.5% of scores falling below the 5<sup>th</sup> percentile).

Table 3 shows the odds ratios for the frequencies of scores below the 10<sup>th</sup> percentile in the premanifest and the manifest HD gene-expansion carriers. For the manifest HD gene-expansion carriers, the odds ratios were significant for all tests except the Brixton test. For the premanifest HD gene-expansion carriers only the odds ratio for Lexical alternating



**Fig. 1.** Frequency of impairment: premanifest HD gene-expansion carriers. Probably impaired scores are on or below the 10<sup>th</sup> percentile and impaired scores are on or below the 5<sup>th</sup> percentile.



**Fig. 2.** Frequency of impairment: manifest HD gene-expansion carriers. Probably impaired scores are on or below the 10<sup>th</sup> percentile and impaired scores are on or below the 5<sup>th</sup> percentile

fluency was significant and one test was trending significance (Semantic/lexical alternating fluency,  $p = .08$ ).

Figure 3 shows the frequency of scores that were *probably impaired* in the premanifest HD gene-expansion carriers when divided by CAPs score. The most frequently impaired tests were generally the same as in Figure 2 (the entire group of premanifest HD gene-expansion carriers) but as expected the frequency of impairment was generally higher for the *medium/high-CAPs* group. For both groups, the most frequently impaired test was Lexical alternating fluency with 37% of scores classified as *probably impaired* in the *medium/high-CAPs* group versus 30% of scores classified as *probably impaired* in the *low-CAPs* group.

**DISCUSSION**


Previous studies on cognition in HD have focused on finding sensitive markers for disease progression by comparing mean differences between groups at different stages of disease (Paulsen, Smith, & Long, 2013; Stout et al., 2011; Tabrizi et al., 2011, 2012). Although these studies have great importance in guiding future research they cannot be taken as a clear indication of *clinically significant cognitive impairment* (Stout et al., 2011). To our knowledge, the frequency of clinically significant cognitive impairment on individual neuropsychological tests has never been investigated in HD gene-expansion carriers. This is the first study to investigate the actual frequency of impaired performances in a large consecutive cohort of HD gene-expansion carriers on a wide range of neuropsychological tests measuring various aspects of executive functions and psychomotor speed.

Group comparisons showed a statistically significant difference between the healthy controls and the premanifest HD-gene expansion carriers on SDMT, Semantic/lexical alternating fluency and Lexical alternating fluency. These results are in accordance with many other studies that have found statistically significant differences on SDMT and verbal fluency for

**Table 3.** Odds ratios and 95% CI for the percentages of HD gene-expansion carriers scoring below the 10<sup>th</sup> percentile relative to healthy controls

	Cutoff scores 10 <sup>th</sup> percentile	Percentage of Premanifest HD gene-expansion carriers below cutoff	Odds ratio (95% CI)	Percentage of Manifest HD gene-expansion carriers below cutoff	Odds ratio (95% CI)
<b>Psychomotor speed</b>					
SDMT (number correct)	41	16%	1.7 (0.5–6.0)	90%	75.3 (18.8–301.7)*
<b>Set-shifting, interference management, and internal attentional control</b>					
Semantic/lexical alternating fluency (number correct)	9	28%	2.6 (0.9–8.1)	73%	18.3 (5.9–301.7)*
Lexical alternating fluency (number correct)	13	34%	3.5 (1.2–10.6)*	83%	34.0 (10.2–113.7)*
Stroop interference test (seconds)	141	16%	1.7 (0.5–6.0)	73%	23.5 (7.0–79.4)*
TMT B (seconds)	89	8%	1.3 (0.2–3.3)	69%	19.3 (5.8–64.0)*
<b>Strategy generation and regulation</b>					
Lexical fluency (number correct)	28	22%	2.5 (0.7–8.5)	58%	12.3 (3.8–40.0)*
<b>Task analysis</b>					
Brixton test (errors)	18	8%	1.3 (0.2–3.3)	23%	2.6 (0.8–8.9)
Zoo map total (number correct)	11	16%	1.4 (0.3–2.2)	46%	3.3 (1.3–8.6)*
Zoo map test part I (seconds)	67	4%	2.0 (0.1–3.2)	33%	6.0 (1.6–22.5)*
<b>Response inhibition</b>					
Hayling interference test (seconds)	85	12%	1.2 (0.3–4.6)	38%	5.3 (1.6–17.2)*

\*Significant at  $p < 0.05$ .



**Fig. 3.** Frequency of impairment: Premanifest HD gene-expansion carriers divided by CAPs score. Probably impaired scores are on or below the 10<sup>th</sup> percentile

premanifest and manifest HD gene-expansion carriers (Holl, Wilkinson, Tabrizi, Painold, & Jahanshahi, 2013; Larsson et al., 2008; Paulsen et al., 2013; Stout et al., 2011). As expected, the manifest HD gene-expansion carriers scored significantly worse than healthy controls on all tests (except one). This is also in line with previous research (Lemiere, Decruyenaere, Evers-Kiebooms, Vandenbussche, & Dom, 2002, 2004).

The frequency of impaired performances in manifest HD gene expansion carriers was substantial on most tests, with SDMT, Lexical alternating fluency, and TMT B being the most frequently impaired. Also the difference in frequency between scores classified as *probably impaired* and *impaired* was small for most tests. This indicates that clinically significant impairment in executive functions and psychomotor speed are frequent once onset of motor symptoms has occurred. For the premanifest HD gene-expansion carriers the most frequently impaired tests were Lexical alternating fluency, Semantic/lexical alternating fluency, and Lexical fluency. Contrary to expectation scores on SDMT were not very frequently impaired. This underlines the fact that a statistically significant difference in mean score does not necessarily indicate the frequency of *clinically significant cognitive impairment* on specific tests, especially if the distribution is somewhat skewed, which is not uncommon in clinical populations. So when choosing tests for clinical neuropsychological assessment, group differences in mean scores may sometimes be misleading and, therefore, cutoff scores for percentiles may be more helpful information for assessing individual patients in the clinical setting.

“Executive functions” is a generic term for a whole range of higher order cognitive processes, and there has been a great deal of debate on how best to measure them (Burgess et al., 2006; Jurado & Rosselli, 2007; Stuss & Alexander, 2007). Part of the challenge is that executive functions are most needed in unstructured situations that pose high demands on monitoring and control of action which in itself

is somewhat contradictory to the typical neuropsychological test situation. This means that even though patients and caregivers might have grave cognitive complaints from everyday life, it might not show in any of the neuropsychological measures used to assess executive functions. Our aim was to investigate which measures of executive functions and psychomotor speed were most frequently impaired in premanifest and manifest HD gene-expansion carriers and would be of important clinical utility for the assessment of individual patients. We applied both measures shown to be sensitive in HD (e.g., SDMT, Stroop test, lexical fluency, TMT B) and neuropsychological tests that have not been investigated in HD populations (e.g., Hayling and Brixton test, Zoo map test, and Alternating fluency). We found no significant differences between the premanifest HD gene-expansion carriers and healthy controls on the Hayling interference test, the Brixton test and the Zoo map test and they were also the tests with the lowest frequency of impairment in HD gene-expansion carriers. This indicates that task analysis and response inhibition are either not affected in premanifest HD gene-expansion carriers or not well measured by these tests. The most frequently impaired test in the premanifest HD gene-expansion carriers were the Alternating fluency tests and Lexical fluency test. This indicates that set-shifting, interference management, internal attentional control, and strategy generation might be some of the earliest affected cognitive functions in HD. This is supported by imaging studies demonstrating early degeneration of the caudate nucleus in HD (Tabrizi et al., 2012) which is connected to the lateral prefrontal cortex through the frontostriatal circuits. Set-shifting and conflict monitoring have previously been associated with the dorsolateral prefrontal cortex (Glascher et al., 2012; Starkstein et al., 1988), and performance on fluency tests in general and especially lexical fluency tests have previously been associated with damage to the prefrontal cortex (Robinson, Shallice, Bozzali, & Cipolotti, 2012).

The frequency of impairment differed between premanifest and manifest HD gene-expansion. The different frequency of impairment for manifest and premanifest HD gene-expansion carriers is not surprising. Some of the test used, for example, SDMT and TMT B pose demands on fine motor skills such as eye movements and handwriting, and performances on these tests will most likely decline concurrently with the evolvement of motor symptoms. The other tests used in this study may be more “pure” cognitive measures. This was supported by our data analysis which showed that covariance analysis with TMT 0 did not change the overall results. In our study, we used the very conservative classification criteria for the HD gene-expansion carriers that were also used in TRACK-HD (Tabrizi et al., 2012). We wanted to investigate cognitive impairment before and independent from any motor symptoms and thus it was important that our premanifest group had no substantial motor signs. This conservative method potentially pushes more people into the manifest HD gene-expansion carrier group than would be clinically diagnosed with HD using the UHDRS Diagnostic confidence levels (Huntington Study Group,

1996), but also ensures that the impairments on cognitive tasks in the premanifest HD gene-expansion carriers are not due to overt motor symptoms.

Disease burden is known to influence neuropsychological test performances in HD gene-expansion carriers (Harrington, Smith, Zhang, Carlozzi, & Paulsen, 2012; Paulsen et al., 2013). Dividing the premanifest HD gene-expansion carriers by CAPs score revealed that the statistically significant group differences were predominantly found for the *medium/high* CAPs group relative to healthy controls. The tests with the most *probably impaired* scores were overall the same for the *low* and *medium/high* CAPs group but the frequency of impaired scores were generally higher in the *medium/high* CAPs group. This indicates, as expected, that the frequency of impaired scores increases with increasing disease burden meaning that cognitive decline in HD gene-expansion carriers is greater the closer to predicted motor onset the person is. This is not surprising since the neurodegeneration also increases with closeness to predicted motor onset (Tabrizi et al., 2012).

Depression has been shown to influence performance on neuropsychological tests (Porter, Bourke, & Gallagher, 2007; Veiel, 1997) and depression is common in HD (Roos, 2010). We investigated the correlation between score on HAM-D and test performances on all nine measures and found a significant positive effect of HAM-D score on Hayling interference test in the premanifest group; otherwise HAM-D score was not significantly associated with neuropsychological test performances in either manifest or premanifest HD gene-expansion carriers. This indicates that, even though it is important to evaluate the effect of depression on neuropsychological tests, executive functions can be affected in HD gene-expansion carriers without symptoms of depression.

From a clinical perspective, it is always important whether the cognitive profile fits with the clinical impression and the types of complaints that HD gene-expansion carriers and their caregivers have when examined. Fluency tests and Alternating fluency have been said to measure mental speed, cognitive flexibility, set-shifting, interference managing, internal attentional control/ monitoring, and strategy generation (Costa et al., 2014; Larsson et al., 2008; Lezak, 2004; Testa et al., 2012; Zec et al., 1999). When premanifest HD gene-expansion carriers and patients with early HD are worried about cognitive decline and referred to neuropsychological assessment, some of the most common complaints they have are problems keeping up at work, especially keeping track of and shifting between assignments and they often describe mental slowing. Since these complaints fit well with what fluency tests, especially alternating fluency tests claim to measure, the inclusion of fluency tests in the clinical neuropsychological assessment of HD gene-expansion carriers might prove useful for detecting early signs of cognitive decline and for follow-up assessments. Detecting the first signs of cognitive impairment can be important for both patients and caregivers to take the precautions needed, for example, to maintain a job, stop driving a car, and when the time comes to get the social services needed to maintain quality of life.

There were some limitations to our study. There was a significant age difference and a significant difference in DART score between the manifest HD gene-expansion carriers and healthy controls and thus the frequency of impairment need to be viewed in that light. It is well known that scores on neuropsychological tests are influenced by age and verbal premorbid intelligence, and, therefore, the frequency of impairment may be lower in the manifest HD gene-expansion carriers if compared to healthy controls with the same age as this subgroup of patients. However, when the results were controlled for age and verbal premorbid intelligence the group differences remained significant for all tests except for the Brixton test, indicating that the effect of background variables was small in our study. Additionally it is important to take into account that premanifest subgroup comparisons that covary age will underestimate effects of group, because these subgroups are defined partly based on age, and actual effects may be stronger than reported here.

The reference group in this study is rather small and this may have led to over or underestimation of cutoff scores especially on the 5<sup>th</sup> percentile which is very unstable in such a small group. Nevertheless in a previously published study by Vinther-Jensen et al. (2014), this same control group was compared to another reference material of 80 healthy adults from a database at the Department of Neurology, Rigshospitalet, University of Copenhagen by regression analyses on a range of cognitive tests. This analysis showed that only 5% could be classified as cognitively impaired by the criteria used in the study. Nonetheless the frequency of impairment on the different neuropsychological tests should ideally be replicated with more extensive reference material (adjusted for age and premorbid intelligence).

To summarize, we found distinct group differences in frequency of impairment on executive measures in manifest and premanifest HD gene-expansion carriers compared to healthy controls, and our results indicate to what degree different executive measures can be expected to be clinically impaired. Based on our results fluency tests, especially Alternating fluency tests, seem to be sensitive in detecting executive deficits in premanifest HD gene-expansion carriers whereas SDMT, even though it is statistically significant in between group comparisons, is less so. This may be because SDMT is a test of psychomotor speed and thus is impaired later on concurrently with the involvement of motor symptoms. In this study executive functions were also affected in premanifest HD-gene expansion carriers far from predicted motor onset, and based on these results it may be advisable to include Alternating fluency tests in cognitive screening and clinical neuropsychological assessment of all HD gene-expansion carriers.

## ACKNOWLEDGMENTS

We thank Thomas William Teasdale for fruitful comments on the manuscript. Ida Unmack Larsen and Tua Vinther-Jensen are both supported by grants from Copenhagen University. Jørgen Erik Nielsen is supported by a research grant from the Novo Nordisk Foundation.



**Conflicts of interest**

None.

**REFERENCES**

- The Huntington's Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell*, *72*, 971–983.
- Huntington Study Group (1996). Unified Huntington's Disease Rating Scale: Reliability and consistency. *Movement Disorders*, *11*, 136–142.
- Alexander, G.E., DeLong, M.R., & Strick, P.L. (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. *Annual Review of Neuroscience*, *9*, 357–381.
- Brandt, J., Inscore, A.B., Ward, J., Shpritz, B., Rosenblatt, A., Margolis, R.L., & Ross, C.A. (2008). Neuropsychological deficits in Huntington's disease gene carriers and correlates of early "conversion". *Journal of Neuropsychiatry and Clinical Neuroscience*, *20*, 466–472. doi:10.1176/appi.neuropsych.20.4.466
- Burgess, P.W., Alderman, N., Forbes, C., Costello, A., Coates, L.M., Dawson, D.R., ... Channon, S. (2006). The case for the development and use of "ecologically valid" measures of executive function in experimental and clinical neuropsychology. *Journal of the International Neuropsychological Society*, *12*, 194–209.
- Burgess, P.W., & Shallice, T. (1997). *The Hayling and Brixton tests*. London: Pearson Assessment.
- Costa, A., Bagoj, E., Monaco, M., Zabberoni, S., De Rosa, S., Papantonio, A.M., ... Carlesimo, G.A. (2014). Standardization and normative data obtained in the Italian population for a new verbal fluency instrument, the phonemic/semantic alternate fluency test. *Neurological Sciences*, *35*, 365–372. doi:10.1007/s10072-013-1520-8
- Crawford, J.R., Parker, D.M., & Besson, J.A. (1988). Estimation of premorbid intelligence in organic conditions. *The British Journal of Psychiatry*, *153*, 178–181.
- Duff, K., Paulsen, J., Mills, J., Beglinger, L.J., Moser, D.J., Smith, M.M., ... Harrington, D.L. (2010). Mild cognitive impairment in prediagnosed Huntington disease. *Neurology*, *75*, 500–507.
- Dumas, E.M., van den Bogaard, S.J., Middelkoop, H.A., & Roos, R.A. (2013). A review of cognition in Huntington's disease. *Frontiers in Bioscience (Scholar Edition)*, *5*, 1–18.
- Duncan, J., Burgess, P., & Emslie, H. (1995). Fluid intelligence after frontal lobe lesions. *Neuropsychologia*, *33*, 261–268.
- Field, A. (2013). *Discovering statistics using IBM SPSS statistics*. Thousand Oaks, CA: Sage.
- Glascher, J., Adolphs, R., Damasio, H., Bechara, A., Rudrauf, D., Calamia, M., ... Tranel, D. (2012). Lesion mapping of cognitive control and value-based decision making in the prefrontal cortex. *Proceedings of the National Academy of Science United States of America*, *109*, 14681–14686.
- Harrington, D.L., Smith, M.M., Zhang, Y., Carlozzi, N.E., & Paulsen, J.S. (2012). Cognitive domains that predict time to diagnosis in prodromal Huntington disease. *Journal of Neurology, Neurosurgery, and Psychiatry*, *83*, 612–619. doi:10.1136/jnnp-2011-301732
- Holl, A.K., Wilkinson, L., Tabrizi, S.J., Painold, A., & Jahanshahi, M. (2013). Selective executive dysfunction but intact risky decision-making in early Huntington's disease. *Movement Disorders*, *28*, 1104–1109. doi:10.1002/mds.25388
- Jurado, M.B., & Rosselli, M. (2007). The elusive nature of executive functions: A review of our current understanding. *Neuropsychology Review*, *17*, 213–233.
- Larsson, M.U., Almkvist, O., Luszcz, M.A., & Wahlin, T.B. (2008). Phonemic fluency deficits in asymptomatic gene carriers for Huntington's disease. *Neuropsychology*, *22*, 596–605. doi:10.1037/0894-4105.22.5.596
- Lemiere, J., Decruyenaere, M., Evers-Kiebooms, G., Vandebussche, E., & Dom, R. (2002). Longitudinal study evaluating neuropsychological changes in so-called asymptomatic carriers of the Huntington's disease mutation after 1 year. *Acta Neurologica Scandinavica*, *106*, 131–141.
- Lemiere, J., Decruyenaere, M., Evers-Kiebooms, G., Vandebussche, E., & Dom, R. (2004). Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation—a longitudinal follow-up study. *Journal of Neurology*, *251*, 935–942.
- Lezak, M.D. (2004). *Neuropsychological assessment*. Oxford: Oxford University Press.
- Montoya, A., Price, B.H., Menear, M., & Lepage, M. (2006). Brain imaging and cognitive dysfunctions in Huntington's disease. *Journal of Psychiatry & Neuroscience*, *31*, 21–29.
- Mortensen, E.L., & Gade, A. (1993). On the relation between demographic variables and neuropsychological test performance. *Scandinavian Journal of Psychology*, *34*, 305–317.
- Nasreddine, Z.S., Phillips, N.A., Bedirian, V., Charbonneau, S., Whitehead, V., Collin, I., ... Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. *Journal of the American Geriatrics Society*, *53*, 695–699.
- Nelson, H.E., & O'Connell, A. (1978). Dementia: The estimation of premorbid intelligence levels using the New Adult Reading Test. *Cortex*, *14*, 234–244.
- Nicoll, D.R., Pirogovsky, E., Woods, S.P., Holden, H.M., Filoteo, J.V., Gluhm, S., ... Gilbert, P.E. (2014). "Forgetting to remember" in Huntington's disease: A study of laboratory, semi-naturalistic, and self-perceptions of prospective memory. *Journal of the International Neuropsychological Society*, *20*, 192–199. doi:10.1017/S1355617713001355
- O'Carroll, R. (2014). The Assessment of premorbid ability: A critical review. *Neurocase*, *1*, 83–89.
- Paulsen, J.S. (2011). Cognitive impairment in Huntington disease: Diagnosis and treatment. *Current Neurology and Neuroscience Reports*, *11*, 474–483. doi:10.1007/s11910-011-0215-x
- Paulsen, J.S., Smith, M.M., & Long, J.D. (2013). Cognitive decline in prodromal Huntington Disease: Implications for clinical trials. *Journal of Neurology, Neurosurgery, and Psychiatry*, *84*, 1233–1239. doi:10.1136/jnnp-2013-305114
- Peinemann, A., Schuller, S., Pohl, C., Jahn, T., Weindl, A., & Kassubek, J. (2005). Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: A neuropsychological and voxel-based morphometric study. *Journal of the Neurological Sciences*, *239*, 11–19.
- Porter, R.J., Bourke, C., & Gallagher, P. (2007). Neuropsychological impairment in major depression: Its nature, origin and clinical significance. *Australian and New Zealand Journal of Psychiatry*, *41*, 115–128.
- Ready, R.E., Mathews, M., Leserman, A., & Paulsen, J.S. (2008). Patient and caregiver quality of life in Huntington's disease. *Movement Disorders*, *23*, 721–726. doi:10.1002/mds.21920
- Reitan, R.M. (1955). The relation of the trail making test to organic brain damage. *Journal of Consulting Psychology*, *19*, 393–394.

- Robinson, G., Shallice, T., Bozzali, M., & Ciolotti, L. (2012). The differing roles of the frontal cortex in fluency tests. *Brain*, *135*, 2202–2214.
- Roos, R.A. (2010). Huntington's disease: A clinical review. *Orphanet Journal of Rare Diseases*, *5*, 40. doi:10.1186/1750-1172-5-40
- Royall, D.R., Lauterbach, E.C., Cummings, J.L., Reeve, A., Rummans, T.A., Kaufer, D.I., ... Coffey, C.E. (2002). Executive control function: A review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. *Journal of Neuropsychiatry and Clinical Neuroscience*, *14*, 377–405.
- Smith, A. (1982). *Symbol digit modalities test: Manual*. Los Angeles: Western Psychological Services.
- Snowden, J., Craufurd, D., Griffiths, H., Thompson, J., & Neary, D. (2001). Longitudinal evaluation of cognitive disorder in Huntington's disease. *Journal of the International Neuropsychological Society*, *7*, 33–44.
- Starkstein, S.E., Brandt, J., Folstein, S., Strauss, M., Berthier, M.L., Pearlson, G.D., ... Folstein, M. (1988). Neuropsychological and neuroradiological correlates in Huntington's disease. *Journal of Neurology, Neurosurgery, and Psychiatry*, *51*, 1259–1263.
- Stout, J.C., Paulsen, J.S., Queller, S., Solomon, A.C., Whitlock, K.B., Campbell, J.C., & Aylward, E.H. (2011). Neurocognitive signs in prodromal Huntington disease. *Neuropsychology*, *25*, 1–14. doi:10.1016/S1474-4422(11)70263-0
- Stout, J.C., Queller, S., Baker, K.N., Cowlishaw, S., Sampaio, C., Fitzer-Attas, C., ... Borowsky, B. (2014). HD-CAB: A cognitive assessment battery for clinical trials in Huntington's disease 1,2,3. *Movement Disorders*, *29*, 1281–1288.
- Stroop, J.R. (1935). Studies of interference in serial verbal reactions. *Journal of Experimental Psychology*, *18*, 643–662.
- Stuss, D.T., & Alexander, M.P. (2007). Is there a dysexecutive syndrome? *Philosophical Transactions of the Royal Society of London. Series B. Biological Sciences*, *362*, 901–915.
- Tabrizi, S.J., Reilmann, R., Roos, R.A., Durr, A., Leavitt, B., Owen, G., ... Langbehn, D.R. (2012). Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: Analysis of 24 month observational data. *The Lancet Neurology*, *11*, 42–53.
- Tabrizi, S.J., Scahill, R.I., Durr, A., Roos, R.A., Leavitt, B.R., Jones, R., ... Stout, J.C. (2011). Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: The 12-month longitudinal analysis. *The Lancet Neurology*, *10*, 31–42. doi:10.1016/S1474-4422(10)70276-3
- Testa, R., Bennett, P., & Ponsford, J. (2012). Factor analysis of nineteen executive function tests in a healthy adult population. *Archives of Clinical Neuropsychology*, *27*, 213–224.
- Unschuld, P.G., Liu, X., Shanahan, M., Margolis, R.L., Bassett, S. S., Brandt, J., ... Ross, C.A. (2013). Prefrontal executive function associated coupling relates to Huntington's disease stage. *Cortex*, *49*, 2661–2673.
- Veiel, H.O. (1997). A preliminary profile of neuropsychological deficits associated with major depression. *Journal of Clinical and Experimental Neuropsychology*, *19*, 587–603.
- Vinther-Jensen, T., Larsen, I.U., Hjermand, L.E., Budtz-Jorgensen, E., Nielsen, T.T., Norremolle, A., ... Vogel, A. (2014). A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease. *Orphanet Journal of Rare Diseases*, *9*, 114. doi:10.1186/s13023-014-0114-8
- Wilson, B.A., Alderman, N., Burgess, P.W., Emslie, H., & Evans, J.J. (1996). *Behavioural assessment of the dysexecutive syndrome: Manual*. Bury St Edmunds, England: Thames Valley Test Company.
- Zec, R.F., Landreth, E.S., Fritz, S., Grames, E., Hasara, A., Frazier, W., ... Manyam, B. (1999). A comparison of phonemic, semantic and alternating word fluency in Parkinson's disease. *Archives of Clinical Neuropsychology*, *14*, 255–264.
- Zhang, Y., Long, J.D., Mills, J.A., Warner, J.H., Lu, W., & Paulsen, J.S. (2011). Indexing disease progression at study entry with individuals at-risk for Huntington disease. *American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics*, *156B*, 751–763. doi:10.1002/ajmg.b.31232